Alphabet Slumps on Revenue Miss as Carvana Jumps After Record Quarter | MarketReader Minute

U.S. stocks decline amid mixed global markets as GDP growth exceeds forecasts but consumer income lags, while European indices await ECB's interest rate decision.

Welcome to the MarketReader Minute.

Below are AI-generated insights on today's premarket moves, powered by MarketReader technology.

Thursday, October 29

Noteworthy macro moves today: Copper +1.6%. DAX 30 Index (Germany) -1.7%. IBEX 35 Index (Spain) -1.6%. Noteworthy US mega-cap moves today: Alphabet Inc. (GOOG) -11.6%. Eli Lilly and Company (LLY) +4.9%. Intel Corp (INTC) -3.3%.

Global equity indices are trading mixed, with U.S. stocks lower while Asian markets show gains. The Nasdaq 100 is particularly under pressure, down significantly following disappointing earnings from Alphabet, which fell over 11% after missing revenue expectations and reporting slower growth in its advertising segment.

In the U.S., economic data released today showed GDP growth rate for Q3 at 3.4%, exceeding forecasts of 3.2%. However, personal income rose by only 0.2%, below expectations of a 0.3% increase, indicating potential concerns about consumer spending power despite overall economic strength.

Initial jobless claims also came in lower than expected at 194k for the week ending October 24, suggesting a resilient labor market; this aligns with the Federal Reserve's view of full employment as they maintain interest rates amid ongoing inflationary pressures.

In Europe, mixed sentiment prevails as the DAX and IBEX indices decline while others like the CAC 40 and FTSE 100 gain ground ahead of the European Central Bank's interest rate decision later today, where rates are expected to remain unchanged amid inflation concerns.

iShares Silver Trust (SLV) [-3.6%]
iShares Silver Trust is trading lower during pre-market hours, reflecting a downward trend amid rising geopolitical tensions and increasing crude oil prices following the Federal Reserve's decision to maintain interest rates. Platinum (XPT/USD) has also declined, driven by concerns over potential U.S. military actions against Iran and their impact on oil supply. Users on social media noted that SLV had risen sharply in January but is now negative for the year, with one user expressing concerns about semiconductor impacts on price movements by year-end or into early 2027. The asset is currently trading significantly below its 20-day moving average and near the lower end of its one-month range.

iShares MSCI South Korea ETF (EWY) [-3.0%]
The iShares MSCI South Korea ETF declined during pre-market hours, influenced by selling pressure in the semiconductor sector, particularly following strong third-quarter results from SK Hynix. Traders took profits after a significant price increase in the stock, contributing to the fund's lower performance. Other semiconductor holdings also experienced declines, although no specific news was reported for them. The overall downward movement in the semiconductor space impacted the ETF's performance. Meanwhile, South Korea's KOSPI index surged significantly today, driven by positive global sentiment after the U.S. Federal Reserve maintained interest rates and Samsung Electronics reported robust quarterly earnings in its semiconductor division.

VanEck Gold Miners ETF (GDX) [-2.3%]
Agnico Eagle Mines, Newmont Corporation, and Barrick Gold reported sharp declines in pre-market trading, following a drop in gold prices amid market volatility after the Federal Reserve's decision to maintain interest rates without clear guidance on future hikes. This volatility has contributed to the declining performance of the VanEck Gold Miners ETF. Additionally, Alamos Gold's disappointing earnings and production figures have further weighed on the ETF's performance. Gold prices are also lower due to geopolitical tensions and rising crude oil prices linked to potential U.S. military action against Iran. Social media posts indicate that users expect a short-term bounce in GDX, while also noting that the larger bearish trend remains intact.

CVNA | +8.6% | +6.1B
Carvana Co | Consumer Discretionary

Carvana Co reported record third-quarter results, with revenue of $8.04 billion, a 42% year-over-year increase that surpassed expectations of $7.7 billion. The company sold 217.38k retail units, marking a significant increase from the previous year, achieving its first quarter above 200k units. Net income rose to $483 million from $263 million a year earlier, although earnings per share of 39 cents missed the consensus estimate of 42 cents. Carvana also refinanced $1.7 billion in senior secured notes, resulting in annual interest savings of approximately $45 million. Following the earnings announcement, shares are sharply higher in pre-market trading. Social media posts noted the CEO's optimism about the company's potential and guidance for a sequential increase in retail sales for the fourth quarter.

MESO | +18.5% | +3.8B
Mesoblast Ltd | Health Care

Mesoblast Ltd reported a 44% increase in net revenue for the fiscal first quarter ended September 30, 2026, with sales of its product Ryoncil reaching $28 million, up from $19 million in the same period last year. The company also announced the completion of patient treatment in the pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain and received positive feedback from the FDA regarding its planned Biologics License Application for the product aimed at preventing gastrointestinal bleeding in end-stage heart failure patients. These developments contributed to a notable increase in the stock price. Earlier in the session, shares advanced sharply higher, reflecting strong momentum following four consecutive sessions of gains.

INSM | +13.7% | +3.3B
Insmed Incorporated | Health Care

Insmed Incorporated reported third-quarter 2026 financial results, revealing significant revenue growth with $524.4 million generated, surpassing analyst expectations of $501.3 million. However, the company posted a net loss of $100.3 million, or $0.46 per share, which was worse than the anticipated loss of $0.39 per share. Insmed raised its full-year revenue guidance for both BRINSUPRI and ARIKAYCE, estimating revenues between $1.35 billion to $1.4 billion and $460 million to $470 million, respectively. The positive news contributed to a notable increase in pre-market trading. Social media posts highlighted mixed results from the earnings report, noting the revenue beat but the EPS miss compared to consensus expectations. Users also pointed to significant growth in BRINSUPRI revenues, indicating positive long-term prospects for the product.

CMG | +7.9% | +3.1B
Chipotle Mexican Grill, Inc. | Consumer Discretionary

Chipotle Mexican Grill, Inc. shares are trading sharply higher following the release of its third-quarter earnings, which showed revenue of $3.293 billion, exceeding expectations of $3.285 billion. Comparable restaurant sales increased by 2.1%, surpassing analyst forecasts, although adjusted earnings per share of 27 cents fell short of the anticipated 29 cents. CEO Scott Boatwright emphasized the effectiveness of their growth strategy, citing three consecutive quarters of positive comparable transaction growth. The company plans to open 340 to 360 new restaurants in 2027. Social media posts highlighted the positive revenue performance but noted the decline in adjusted EPS and restaurant-level margins. Users also pointed out that digital sales accounted for 38.8% of total food and beverage sales during the quarter.

GKOS | +16.1% | +2.0B
Glaukos Corporation | Health Care

Glaukos Corporation's stock is advancing sharply in pre-market trading, driven by multiple analyst price target increases following the company's strong third-quarter results. Needham analyst David Saxon raised his target to $251 from $201, while Stifel's Thomas Stephan set a new target at $225. Additionally, Wells Fargo's Larry Biegelsen increased his price target to $226 from $178. The company's Q3 earnings report showed a 58% year-over-year revenue growth to $211 million and a return to profitability, prompting Glaukos to raise its full-year 2026 revenue guidance to between $775 million and $785 million. Users on X noted significant after-hours activity for Glaukos, highlighting the stock's sharp rise following the earnings announcement.

Thank you for spending a minute with us.

If you have 2 more minutes, watch this demo of the MarketReader Platform:

Stay in the Loop

Check the MarketReader blog for the latest news, and follow us on X (Twitter) for real-time market insights: @marketreader_AI